Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01810744 | Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma(BEVACAPI) | completed | N/A | 47 | Centre Georges Francois LeclercOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT02768389 | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | completed | Early Phase 1 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2019 |
| clinicaltrials |
| NCT03869242 | NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM(NovoTTF-200A) | unknown | N/A | 60 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Mar 11, 2019 | clinicaltrials |
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors(Zactima) | completed | Phase 1 / Phase 2 | 119 | Patrick Y. Wen, MDOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02189109 | The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma(GBM) | completed | Phase 1 | 11 | NuvOx LLCINDUSTRY | 1 | Feb 28, 2019 | clinicaltrials |
| NCT02575027 | Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme | completed | N/A | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | withdrawn | — | 0 | Duke UniversityOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03687034 | A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma | unknown | Phase 1 | 21 | Leaf Vertical Inc.INDUSTRY | 0 | Feb 26, 2019 | clinicaltrials |
| NCT00977431 | Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform | completed | Phase 1 | 36 | Boehringer IngelheimINDUSTRY | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01873469 | Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme | completed | — | 102 | Technische Universität DresdenOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Duke UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03293888 | Spectral Analysis Probe to Identify Glioblastoma Cells | terminated | — | 12 | University of OklahomaOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01562197 | A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma(AxiGII) | completed | Phase 2 | 56 | Bart NeynsOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT03291314 | Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma(GliAvAx) | completed | Phase 2 | 52 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01846871 | Tivozanib for Recurrent Glioblastoma | completed | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT03780569 | TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM | unknown | N/A | 10 | NovoCure Ltd.INDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03642080 | MRI Predictors of Response to Tumor Treating Fields | unknown | — | 48 | New York Presbyterian Brooklyn Methodist HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT03746288 | To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) | unknown | Phase 2 | 60 | CANbridge Life Sciences Ltd.INDUSTRY | 0 | Nov 19, 2018 | clinicaltrials |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | terminated | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT02853565 | A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 10 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01653834 | Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas | completed | N/A | 10 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT02728349 | Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma | completed | Phase 1 | 26 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., LtdINDUSTRY | 1 | Nov 1, 2018 | clinicaltrials |
| NCT02966509 | Engagement of Patients With Advanced Cancer(EPAC) | completed | N/A | 213 | Stanford UniversityOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT00038493 | Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02511405 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)(GLOBE) | completed | Phase 3 | 252 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 3 | Oct 23, 2018 | clinicaltrials |
| NCT02718443 | VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | completed | Phase 1 | 14 | Vaximm GmbHINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients | terminated | Phase 2 | 10 | PIQUR Therapeutics AGINDUSTRY | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02253212 | Safety of BBB Opening With the SonoCloud(SONOCLOUD) | completed | Phase 1 / Phase 2 | 27 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00323115 | Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 11 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01967758 | Phase I Study of Safety and Immunogenicity of ADU-623 | completed | Phase 1 | 11 | Providence Health & ServicesOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT02062372 | Spatial Analysis and Validation of Glioblastoma on 7 T MRI | terminated | N/A | 5 | Maastricht Radiation OncologyOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT02176720 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | terminated | Phase 1 | 31 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT02666066 | Radiomics for Prediction of Survival in GBM(Radiomics) | completed | — | 289 | Maastricht Radiation OncologyOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03631836 | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma(MARELLE01) | unknown | Phase 1 | 34 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01112527 | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | completed | Phase 2 | 58 | Massachusetts General HospitalOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT03633552 | Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma | unknown | Phase 3 | 62 | Mashhad University of Medical SciencesOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT03631823 | Gut Microbiota and Glioblastoma Multiforme Prognosis | unknown | — | 200 | Huashan HospitalOTHER | 0 | Aug 15, 2018 | clinicaltrials |
| NCT02049489 | A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma | completed | Phase 1 | 20 | Precision Life Sciences GroupINDUSTRY | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02149225 | GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients | completed | Phase 1 | 16 | Immatics Biotechnologies GmbHINDUSTRY | 5 | Aug 7, 2018 | clinicaltrials |
| NCT00679354 | Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Aug 1, 2018 | clinicaltrials |
| NCT01103375 | Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma | terminated | Phase 1 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01151670 | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | terminated | Phase 2 | 8 | Michael Vogelbaum, MD, PhDOTHER | 1 | Jul 31, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 15, 2019source: clinicaltrials